Drug Discovery

Linkers for protein degradation

Article metrics

The ability to subvert E3 ubiquitin ligases with small-molecule drugs offers tremendous promise for drug discovery. A new study demonstrates how structural and computational techniques can engineer and exploit unnatural protein–protein interfaces to design selective protein degraders.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Comparison of degradation strategies.

References

  1. 1.

    Sakamoto, K. M. et al. Proc. Natl. Acad. Sci. USA 98, 8554–8559 (2001).

  2. 2.

    Nowak, R.P. et al. Nat. Chem. Biol. https://doi.org/10.1038/s41589-018-0055-y (2018).

  3. 3.

    Ito, T. et al. Science 327, 1345–1350 (2010).

  4. 4.

    Matyskiela, M. E. et al. Nature 535, 252–257 (2016).

  5. 5.

    Petzold, G., Fischer, E. S. & Thomä, N. H. Nature 532, 127–130 (2016).

  6. 6.

    Tan, X. et al. Nature 446, 640–645 (2007).

  7. 7.

    Lu, J. et al. Chem. Biol. 22, 755–763 (2015).

  8. 8.

    Winter, G. E. et al. Science 348, 1376–1381 (2015).

  9. 9.

    Gadd, M. S. et al. Nat. Chem. Biol. 13, 514–521 (2017).

Download references

Author information

Correspondence to Philip P. Chamberlain.

Ethics declarations

Competing interests

The author is an employee and shareholder at Celgene.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

P. Chamberlain, P. Linkers for protein degradation. Nat Chem Biol 14, 639–640 (2018) doi:10.1038/s41589-018-0057-9

Download citation

Further reading